

**Table 4. Costs per patient population, per regimen, per year**

<b>Intervention</b>	<b>Number of patients per year</b>	<b>Total cost per year</b>
<b>Neoadjuvant treatment according to response</b>		
Neoadjuvant nivolumab plus ipilimumab	24	£££
Neoadjuvant nivolumab plus ipilimumab plus adjuvant dabrafenib and trametinib	11	£££
Neoadjuvant nivolumab plus ipilimumab plus adjuvant nivolumab monotherapy	6	£££
Total cost of treatment under consideration per year		£££
<b>Comparators – SOC</b>		
Adjuvant treatment - dabrafenib and trametinib	12	£££
Adjuvant treatment - nivolumab monotherapy	4	£££
Adjuvant treatment – pembrolizumab monotherapy	25	£££
Total cost of SOC treatment per year		£££
<b>Annual cost difference</b>		£££
<p>£££: commercial in confidence figure removed                      Includes the following costs: medicines acquisition, medicines administration, adverse event management, and resource (where applicable).                      Calculations are based on 41 patients.                      Costs exclude VAT.                      Patient Access Scheme prices used.</p>		